Exicure Past Earnings Performance
Past criteria checks 4/6
Exicure's earnings have been declining at an average annual rate of -4.8%, while the Biotechs industry saw earnings growing at 12.3% annually. Revenues have been growing at an average rate of 39.8% per year. Exicure's return on equity is 31.6%, and it has net margins of 12.9%.
Key information
-4.8%
Earnings growth rate
16.2%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 39.8% |
| Return on equity | 31.6% |
| Net Margin | 12.9% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Little Excitement Around Exicure, Inc.'s (NASDAQ:XCUR) Revenues As Shares Take 25% Pounding
Aug 29
Exicure to get $5.4M equity financing, reduce workforce & end R&D, preclinical activities
Sep 26Exicure Q2 GAAP loss per share narrows, revenue up
Aug 15Exicure regains compliance with Nasdaq's minimum bid price requirement
Jul 20Exicure slides 31% as it implements reverse-stock-split to get back Nasdaq compliance
Jun 29Does Exicure (NASDAQ:XCUR) Have A Healthy Balance Sheet?
Aug 25Does Exicure (NASDAQ:XCUR) Have A Healthy Balance Sheet?
Mar 10A Look At Exicure's (NASDAQ:XCUR) Share Price Returns
Jan 13Exicure announces issuance of two new U.S. patents, and new patent allowance
Dec 21How Much Of Exicure, Inc. (NASDAQ:XCUR) Do Institutions Own?
Dec 15Exicure (XCUR) Investor Presentation - Slideshow
Nov 18Revenue & Expenses BreakdownBeta
How Exicure makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 24 | 3 | 12 | -11 |
| 31 Mar 23 | 26 | 1 | 10 | 0 |
| 31 Dec 22 | 29 | -3 | 11 | 0 |
| 30 Sep 22 | 9 | -35 | 13 | 14 |
| 30 Jun 22 | 3 | -53 | 13 | 14 |
| 31 Mar 22 | 1 | -60 | 13 | 0 |
| 31 Dec 21 | 0 | -64 | 13 | 0 |
| 30 Sep 21 | -2 | -63 | 12 | 0 |
| 30 Jun 21 | 4 | -48 | 11 | 0 |
| 31 Mar 21 | 8 | -38 | 10 | 0 |
| 31 Dec 20 | 17 | -25 | 10 | 0 |
| 30 Sep 20 | 17 | -22 | 9 | 0 |
| 30 Jun 20 | 15 | -19 | 9 | 0 |
| 31 Mar 20 | 10 | -20 | 9 | 0 |
| 31 Dec 19 | 1 | -26 | 9 | 0 |
| 30 Sep 19 | 1 | -21 | 8 | 0 |
| 30 Jun 19 | 1 | -21 | 8 | 0 |
| 31 Mar 19 | 0 | -22 | 8 | 0 |
| 31 Dec 18 | 0 | -22 | 8 | 0 |
| 30 Sep 18 | 2 | -21 | 8 | 0 |
| 30 Jun 18 | 5 | -18 | 8 | 0 |
| 31 Mar 18 | 7 | -14 | 8 | 0 |
| 31 Dec 17 | 10 | -11 | 7 | 0 |
| 30 Sep 17 | 8 | -13 | 6 | 0 |
| 30 Jun 17 | 6 | -15 | 5 | 0 |
| 31 Mar 17 | 3 | -16 | 4 | 0 |
| 31 Dec 16 | 1 | -17 | 4 | 0 |
| 31 Dec 15 | 2 | -6 | 5 | 0 |
Quality Earnings: XCUR has high quality earnings.
Growing Profit Margin: XCUR became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: XCUR has become profitable over the past 5 years, growing earnings by -4.8% per year.
Accelerating Growth: XCUR has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: XCUR has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: XCUR's Return on Equity (31.6%) is considered high.